{"id":2060,"date":"2023-09-13T19:59:00","date_gmt":"2023-09-13T19:59:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/"},"modified":"2023-10-18T12:06:49","modified_gmt":"2023-10-18T12:06:49","slug":"xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/","title":{"rendered":"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million"},"content":{"rendered":"
\n

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. ADDITIONAL RESTRICTIONS APPLY, PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.<\/p>\n<\/div>\n

\n

XVIVO Perfusion AB (publ) (\u201cXVIVO\u201d or the \u201cCompany\u201d) has completed a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share (the \u201cDirected Issue\u201d), through which the Company receives SEK 440 million before deduction of transaction costs. The subscription price was determined through an accelerated book-building procedure conducted by Carnegie Investment Bank AB (publ) (\u201cCarnegie\u201d) and DNB Markets, a part of DNB Bank ASA, Sweden branch (\u201cDNB Markets\u201d) to act as Joint Bookrunners (together the \u201cJoint Bookrunners\u201d).<\/strong><\/p>\n<\/div>\n

\n

The Directed Issue<\/strong>
The board of directors of XVIVO has, based on the authorization to issue shares granted by the annual general meeting on 25 April 2023 and as announced by the Company through a press release earlier today, resolved on a directed issue of 1,600,000 shares at a subscription price of SEK 275 per share, corresponding to the closing price on the day of this announcement of the XVIVO share, as traded on Nasdaq Stockholm, consequently raising gross proceeds of SEK 440 million. The subscription price in the Directed Issue was determined through an accelerated book-building procedure led by the Joint Bookrunners and was, accordingly, in the assessment of the board of directors reflects market conditions and the demand for the Company's shares.<\/p>\n

Investors in the Directed Issue include both existing and new shareholders such as Bure Equity AB, the Fourth AP Fund, Swedbank Robur Fonder, Eccenovo, Handelsbanken Fonder AB through the investment fund H\u00e4lsov\u00e5rd Tema, the Third AP Fund and a tier-one global international investor.<\/p>\n

The interest from US clinics for XVIVO\u2019s upcoming US heart preservation trial has been significant. On July 25, 2023, the FDA granted XVIVO approval to include Donation after Circulatory Death (\u201cDCD<\/strong>\u201d) hearts in its Investigational Device Exemption (\u201cIDE<\/strong>\u201d) clinical trial. Expanding the clinical trial to include DCD hearts means that the Company\u2019s technology is additionally made available to approximately one third of the US donor pool.<\/p>\n

Today, XVIVO is the European market leader within liver machine perfusion, supported by strong clinical data published in leading scientific journals. In 2022, 9,528 liver transplants were performed in the US (UNOS data). In order to become the the global market leader within abdominal machine perfusion, the Company has identified an opportunity to shorten the time to market in the US for the Liver Assist technology. This can be achieved by conducting a clinical trial to support the FDA PMA approval process for the Liver Assist in addition to the Company\u2019s heart preservation trial, meaning that the Company aims to conduct regulatory processes for both heart and liver in the US.<\/p>\n

The net proceeds from the Directed Issue are intended to be used for:
\u00b7 Increased investment in US clinical trial infrastructure and support to create an efficient FDA PMA regulatory approval process for the heart preservation technology;
\u00b7 Fast-track the preparation and start of the clinical trial and FDA PMA regulatory approval process for Liver Assist; and
\u00b7 Scale-up of disposable production to ensure delivery capacity and decrease in cost of goods sold.<\/p>\n

Prior to the Directed Issue, the Company's board of directors has made an overall assessment and carefully considered the possibility to raise capital through a rights issue with preferential right for the Company's existing shareholders. The board of directors considers that the reasons for deviating from the shareholders\u2019 preferential right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for a adverse effect on the share price, particularly in light of the current market volatility and the challenging market conditions, (ii) to diversify and strengthen the Company's shareholder base with international institutional investors, (iii) to carry out a directed share issue can be made at lower costs and with less complexity than a rights issue and in light of the current market conditions, the board of directors has assessed that a rights issue would also require external underwriting from a guarantor syndicate that would entail additional significant. Considering the above, the board of directors has made the assessment that a directed share issue with deviation from the shareholders\u2019 preferential right is the most favourable alternative for XVIVO, creates value for the Company and is in the best interest of the Company\u2019s shareholders. The board of directors thus considers that the reasons outweigh the main rule that new share issues are to be carried out with preferential rights for the shareholders.<\/p>\n

The Directed Issue entails a dilution of approximately 5.1 percent of the number of shares and votes in the Company (calculated as the number of newly issued shares divided by the total number of shares in the Company after the Directed Issue). Through the Directed Issue, the number of shares and votes in the Company will increase by 1,600,000 from 29,899,470 to 31,499,470. The share capital will increase by approximately SEK 40,894.01 from approximately SEK 764,193.202576 to approximately SEK 805,087. 212576.
Settlement of the Directed Issue is expected to take place on or about 18 September 2023.<\/p>\n

Lock-up undertakings<\/strong>
<\/strong>In connection with the Directed Issue, the Company has agreed to a lock-up undertaking, with customary exceptions, on future share issuances for a period of 180 calendar days after the settlement date of the Directed Issue. In addition, XVIVO\u2019s board members and shareholding members of the senior management have undertaken not to, subject to customary exceptions, divest any shares in XVIVO for a period of 180 days from the settlement date of the Directed Issue.<\/p>\n

Advisors<\/strong>
<\/strong>Carnegie and DNB Markets acted as Joint Bookrunners in connection with the Directed Issue. Advokatfirman Vinge acted as legal counsel to the Company and Baker McKenzie acted as legal counsel to the Joint Bookrunners.<\/p>\n

13 September 2023
Gothenburg
XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n

\n

For further information, please contact:<\/strong><\/p>\n\n

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer\u00a0Nordstr\u00f6m, CFO, +46 73 519 21 64, e-mail:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n

\n

This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-13 21:59 CEST.<\/em><\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com\/us.<\/p>\n<\/div>\n

\n

Important information<\/strong><\/p>\n\n

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer to sell or an offer, or the solicitation of an offer, to acquire or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction. This announcement is not a prospectus for the purposes of Regulation (EU) 2017\/1129 (the \u201cProspectus Regulation\u201d) and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of shares or other securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.<\/p>\n

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa, South Korea or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.<\/p>\n

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, \u201cqualified investors\u201d who are (i) persons having professional experience in matters relating to investments who fall within the definition of \u201cinvestment professionals\u201d in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the \u201cOrder\u201d); or (ii) high net worth entities falling within Article 49 (2)(a) to (d) of the Order (all such persons together being referred to as \u201crelevant persons\u201d). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.<\/p>\n

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for shares in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company\u2019s shares. Such information has not been independently verified by the Joint Bookrunners. The Joint Bookrunners are acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.
The information in this press release may not be forwarded or distributed to any other person and may not be reproduced at all. Any forwarding, distribution, reproduction or disclosure of this information in its entirety or in any part is prohibited. Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.<\/p>\n

This press release does not constitute an invitation to warrant, subscribe, or otherwise acquire or transfer any securities in any jurisdiction. This press release does not constitute a recommendation for any investors\u2019 decisions regarding the Directed Issue. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company\u2019s website nor any other website accessible through hyperlinks on the Company\u2019s website are incorporated into or form part of this press release.<\/p>\n

Forward-looking statements<\/strong>
This press release contains forward-looking statements that reflect the Company\u2019s intentions, beliefs, or current expectations about and targets for the Company\u2019s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as \u201cbelieve\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201caim\u201d or \u201cmight\u201d, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq Stockholm\u2019s Rulebook for Issuers.<\/p>\n

Information to distributors<\/strong>
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014\/65\/EU on markets in financial instruments, as amended (\u201cMiFID II\u201d); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017\/593 supplementing MiFID II; and (c) local implementing measures (together, the \u201cMiFID II Product Governance Requirements\u201d), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any \u201cmanufacturer\u201d (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in the Company have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the \u201cTarget Market Assessment\u201d). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.<\/p>\n

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.<\/p>\n

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.<\/p>\n

This is a translation of the Swedish version of the press release. In case of discrepancies, the Swedish wording shall prevail.<\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES,…<\/p>\n","protected":false},"template":"","class_list":["post-2060","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca-shares","mfn-news-tag-mfn-ca-shares-issuance","mfn-news-tag-mfn-cus-disclaimer","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-ca"],"acf":[],"yoast_head":"\nXVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO\" \/>\n<meta property=\"og:description\" content=\"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-18T12:06:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\\\/\",\"name\":\"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2023-09-13T19:59:00+00:00\",\"dateModified\":\"2023-10-18T12:06:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO","og_description":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES,...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/","og_site_name":"United States","article_modified_time":"2023-10-18T12:06:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/","name":"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2023-09-13T19:59:00+00:00","dateModified":"2023-10-18T12:06:49+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-has-carried-out-a-directed-share-issue-of-1600000-shares-at-a-subscription-price-of-sek-275-per-share-raising-gross-proceeds-of-sek-440-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO has carried out a directed share issue of 1,600,000 shares at a subscription price of SEK 275 per share, raising gross proceeds of SEK 440 million"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}